120 related articles for article (PubMed ID: 16122187)
21. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo.
Rogers PM; Beale PJ; Al-Moundhri M; Boxall F; Patterson L; Valenti M; Raynaud F; Hobbs S; Johnston S; Kelland LR
Int J Cancer; 2002 Feb; 97(6):858-63. PubMed ID: 11857368
[TBL] [Abstract][Full Text] [Related]
24. A proposed mechanism for the inhibitory effect of the anticancer agent titanocene dichloride on tumour gelatinases and other proteolytic enzymes.
Pavlaki M; Debeli K; Triantaphyllidou IE; Klouras N; Giannopoulou E; Aletras AJ
J Biol Inorg Chem; 2009 Aug; 14(6):947-57. PubMed ID: 19390879
[TBL] [Abstract][Full Text] [Related]
25. Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model.
Gomez-Roman N; McGregor F; Wheate NJ; Plumb JA
J Ovarian Res; 2015 Sep; 8():62. PubMed ID: 26384969
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.
Gontero P; Casetta G; Zitella A; Ballario R; Pacchioni D; Magnani C; Muir GH; Tizzani A
Eur Urol; 2000 Sep; 38(3):287-96. PubMed ID: 10940702
[TBL] [Abstract][Full Text] [Related]
27. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Ramsey SD; Moinpour CM; Lovato LC; Crowley JJ; Grevstad P; Presant CA; Rivkin SE; Kelly K; Gandara DR
J Natl Cancer Inst; 2002 Feb; 94(4):291-7. PubMed ID: 11854391
[TBL] [Abstract][Full Text] [Related]
28. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
Lokich JJ; Anderson N; Bern M; Coco F; Dow E
Cancer; 1999 Jan; 85(2):499-503. PubMed ID: 10023721
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
30. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
Bar JK; Harłozińska A; Popiela A; Noga L
Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
[TBL] [Abstract][Full Text] [Related]
31. Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas.
Köpf-Maier P
J Cancer Res Clin Oncol; 1987; 113(4):342-8. PubMed ID: 3036884
[TBL] [Abstract][Full Text] [Related]
32. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
Lengyel E; Litchfield LM; Mitra AK; Nieman KM; Mukherjee A; Zhang Y; Johnson A; Bradaric M; Lee W; Romero IL
Am J Obstet Gynecol; 2015 Apr; 212(4):479.e1-479.e10. PubMed ID: 25446664
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
34. [Biological effect of down-regulating of MTRR gene on cisplatin-resistant ovarian cancer SKOV3 cells in vitro and in vivo studies].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):126-34. PubMed ID: 26917482
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
36. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.
Kelter G; Sweeney NJ; Strohfeldt K; Fiebig HH; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1091-8. PubMed ID: 16222151
[TBL] [Abstract][Full Text] [Related]
37. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.
Pratesi G; Perego P; Polizzi D; Righetti SC; Supino R; Caserini C; Manzotti C; Giuliani FC; Pezzoni G; Tognella S; Spinelli S; Farrell N; Zunino F
Br J Cancer; 1999 Aug; 80(12):1912-9. PubMed ID: 10471039
[TBL] [Abstract][Full Text] [Related]
38. VEGF antibody plus cisplatin reduces angiogenesis and tumor growth in a xenograft model of ovarian cancer.
Ghosh S; Maity P
J Environ Pathol Toxicol Oncol; 2010; 29(1):17-30. PubMed ID: 20528744
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of cytotoxic activity of titanocene difluorides and determination of their mechanism of action in ovarian cancer cells.
Koubkova L; Vyzula R; Karban J; Pinkas J; Ondrouskova E; Vojtesek B; Hrstka R
Invest New Drugs; 2015 Oct; 33(5):1123-32. PubMed ID: 26205069
[TBL] [Abstract][Full Text] [Related]
40. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells.
O'Connor K; Gill C; Tacke M; Rehmann FJ; Strohfeldt K; Sweeney N; Fitzpatrick JM; Watson RW
Apoptosis; 2006 Jul; 11(7):1205-14. PubMed ID: 16699961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
